Danny’s has a strong background in preclinical animal models of psychiatric disorders including addiction, anxiety, and obsessive-compulsive disorder. He has expertise in neuroanatomy, behavioral pharmacology, cell signaling, mouse genetics, immunohistochemistry, and fluorescent imaging. Danny believes that psychiatric diseases, especially the ones that are difficult to treat with conventional pharmacotherapies, are circuit-based disorders that require both experiential and neurochemical interventions. This is why he is so passionate about the potential of psychedelic-assisted psychiatry to transform the way we treat mental illness. Danny aims to help elucidate the mechanisms by which rapidly-acting antidepressants and psychoplastogens can facilitate meaningful improvements in treatment outcomes for people with refractory psychiatric diseases.
Entactogenic drugs like MDMA and psychedelics like psilocybin may be beneficial for a range of psychiatric disorders. Though the pharmacology and subjective effects of entactogens and psychedelics differ, drugs that display qualities of both have received little attention to date.